Antibody, Doctors, In-Vitro and In-Vivo - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Antibody

Doctors

In-Vitro

In-Vivo

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. DS: The company now has clients across big pharma.

Antibody

Antibody Gene Therapy Gene In-Vitro

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

These have been the most promising form of antibodies being developed, with Ipilimumab (CTLA4 blocking) and Nivolumab (PD1 blocking) now approved by the US Food and Drug Administration (FDA) for more than nine cancer types. Half of people diagnosed with cancer in England and Wales survive their disease for 10 years or more (2010-11) 1.

Research

Research In-Vitro In-Vivo Development

Turning science into business: An optimised alternative to antibodies

The evolution of assays for immuno-oncology research

Stay Connected